Personalized Cancer Vaccine for Advanced Colon or Pancreatic Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized cancer vaccine (ODI-2001) combined with standard chemotherapy in patients with advanced colon or pancreatic cancer that cannot be surgically removed. The vaccine is designed specifically for each patient's tumor to help their immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced or metastatic colon cancer (microsatellite stable type) or pancreatic cancer that cannot be treated with surgery
- Good overall health status (able to walk around and do light activities)
- Able to start standard chemotherapy treatments for your cancer type
- Blood work, kidney, and liver function within acceptable ranges
- Willing to have tumor biopsies (tissue samples) and blood tests as part of the study
- No active infections, HIV, or hepatitis; not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
This Phase 1 study tests a personalized vaccine made from a patient’s tumor to help the immune system recognize and attack cancer. It is for people with advanced pancreatic or colorectal cancer (often after surgery or while metastatic) and aims to see if the approach is safe and can help immune control of the cancer.
This trial tests a personalized mRNA vaccine made from your tumor’s unique genetic features. It is given after surgery to prevent the pancreatic cancer from coming back.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.